Le medicament du mois. Combinaison fixe ezetimibe-rosuvastatine (Myrosor(R)). ; Ezetimibe-rosuvastatin fixed-dose combination (Myrosor(R))

peer reviewed ; LDL cholesterol targets are increasingly strict in recent international guidelines, especially in patients at very high or high cardiovascular risk. To reach these targets, it is recommended to use a potent statin, with a titration up to the maximal tolerated dose and, if not sufficient, to combine ezetimibe, a medication that blocks the intestinal absorption of cholesterol. This association allows reduce the dose of statin, while keeping an excellent cholesterol-lowering efficacy and favouring a good tolerance profile. This article describes the characteristics of a fixed-dose... Mehr ...

Verfasser: WALLEMACQ, Caroline
Scheen, André
Dokumenttyp: journal article
Erscheinungsdatum: 2020
Verlag/Hrsg.: Université de Liège. Revue Médicale de Liège
Schlagwörter: Anticholesteremic Agents/administration & dosage / Belgium / Cholesterol / LDL / Drug Therapy / Combination / Ezetimibe/administration & dosage / Humans / Hydroxymethylglutaryl-CoA Reductase Inhibitors / Hypercholesterolemia/drug therapy / Rosuvastatin Calcium/administration & dosage / Treatment Outcome / Cardiovascular / Ezetimibe / Fixed / Rosuvastatin / dose combination / Human health sciences / Pharmacy / pharmacology & toxicology / Endocrinology / metabolism & nutrition / Sciences de la santé humaine / Pharmacie / pharmacologie & toxicologie / Endocrinologie / métabolisme & nutrition
Sprache: Französisch
Permalink: https://search.fid-benelux.de/Record/base-29356677
Datenquelle: BASE; Originalkatalog
Powered By: BASE
Link(s) : https://orbi.uliege.be/handle/2268/246847

peer reviewed ; LDL cholesterol targets are increasingly strict in recent international guidelines, especially in patients at very high or high cardiovascular risk. To reach these targets, it is recommended to use a potent statin, with a titration up to the maximal tolerated dose and, if not sufficient, to combine ezetimibe, a medication that blocks the intestinal absorption of cholesterol. This association allows reduce the dose of statin, while keeping an excellent cholesterol-lowering efficacy and favouring a good tolerance profile. This article describes the characteristics of a fixed-dose combination of rosuvastatin, the most potent statin, and ezetimibe, commercialized in Belgium under the trade name Myrosor(R).